Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida. Show more
Location: 100 SE 2nd Street, Miami, FL, 33131, United States | Website: https://telomirpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
45.38M
52 Wk Range
$1.12 - $7.08
Previous Close
$1.32
Open
$1.33
Volume
197,539
Day Range
$1.30 - $1.38
Enterprise Value
45.48M
Cash
7.329M
Avg Qtr Burn
-773.2K
Insider Ownership
44.98%
Institutional Own.
6.82%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
